Publications

ESMO open

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

01-04-2023

BMC cancer

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

04-03-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

01-03-2023

Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023

Cancer cell

Base editing screens map mutations affecting interferon-γ signaling in cancer.

13-02-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Journal of proteome research

Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation.

06-01-2023

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key Publication

ESMO open

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

01-12-2022

The Journal of pathology

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.

01-10-2022

European journal of cancer (Oxford, England : 1990)

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

01-08-2022

Cancer discovery

Can Drug Repurposing Accelerate Precision Oncology?

06-07-2022

Frontiers in medicine

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

02-07-2022

Cancer chemotherapy and pharmacology

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

01-07-2022

Cell reports. Medicine

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

21-06-2022

Nature cancer

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

01-05-2022

The Lancet. Oncology

The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply.

01-05-2022

Nature medicine

Delivering precision oncology to patients with cancer.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Nature cancer

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

01-02-2022

The Lancet. Oncology

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.

01-02-2022

Cancers

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.

16-01-2022

Frontiers in medicine

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

28-12-2021

Clinical cancer research : an official journal of the American Association for Cancer Research

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

15-11-2021

Molecular oncology

The Porto European Cancer Research Summit 2021.

01-10-2021

Cancer cell

Tumor organoids: Opportunities and challenges to guide precision medicine.

13-09-2021

Nature medicine

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.

01-09-2021

Cancer cell

Developing and validating model systems for immuno-oncology.

09-08-2021

Cancer discovery

Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.

01-08-2021

ESMO open

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.

01-06-2021

Frontiers in endocrinology

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

30-03-2021

BMC medical genomics

Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).

10-11-2020

Clinical and translational radiation oncology

Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.

01-09-2020

Molecular oncology

Towards a cancer mission in Horizon Europe: recommendations.

01-08-2020

Nature medicine

Author Correction: Caring for patients with cancer in the COVID-19 era.

01-07-2020

Nature medicine

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.

01-07-2020

Learning health systems

Learning health care systems: Highly needed but challenging.

01-07-2020

Nature communications

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

22-06-2020

Nature communications

Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing.

05-06-2020

European journal of cancer (Oxford, England : 1990)

Patients with cancer in the era of 2019 novel coronavirus disease.

01-06-2020

Cell reports

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.

05-05-2020

Nature medicine

Caring for patients with cancer in the COVID-19 era.

01-05-2020

Nature medicine

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

01-04-2020

Molecular cancer research : MCR

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity.

01-04-2020

ESMO open

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.

01-04-2020

The Journal of pathology

BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.

01-02-2020

Nature protocols

Tumor organoid-T-cell coculture systems.

01-01-2020

Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019

Nature

Pan-cancer whole-genome analyses of metastatic solid tumours.

01-11-2019

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

Base editing screens map mutations affecting interferon-γ signaling in cancer.

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation.

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

Can Drug Repurposing Accelerate Precision Oncology?

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply.

Delivering precision oncology to patients with cancer.

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

The Porto European Cancer Research Summit 2021.

Tumor organoids: Opportunities and challenges to guide precision medicine.

Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.

Developing and validating model systems for immuno-oncology.

Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy.

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).

Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.

Towards a cancer mission in Horizon Europe: recommendations.

Author Correction: Caring for patients with cancer in the COVID-19 era.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.

Learning health care systems: Highly needed but challenging.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing.

Patients with cancer in the era of 2019 novel coronavirus disease.

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.

Caring for patients with cancer in the COVID-19 era.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity.

Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer.

BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.

Tumor organoid-T-cell coculture systems.

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

Pan-cancer whole-genome analyses of metastatic solid tumours.

This site uses cookies

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.